Australia
|
Not Applicable
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(I.R.S. Employer Identification No.)
|
Telix Pharmaceuticals Limited
55 Flemington Road
North Melbourne, Victoria, 3051, Australia
|
Not Applicable
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Smaller reporting company ☐
|
Emerging growth company ☒
|
Item 1. |
Plan Information.
|
Item 2. |
Registrant Information and Employee Plan Annual Information.
|
Item 3. | Incorporation of Documents by Reference. |
Item 4. |
Description of Securities.
|
Item 5. |
Interests of Named Experts and Counsel.
|
Item 6.
|
Indemnification of Directors and Officers.
|
• |
a liability owed to the company or a related body corporate of the company;
|
• |
a liability for a pecuniary penalty order made under section 1317G or a compensation order under section 961M, 1317H, 1317HA, 1317HB, 1317HC or 1317HE of the Australian Corporations Act;
|
• |
a liability that is owed to someone other than the company or a related body corporate of the company and did not arise out of conduct in good faith; or
|
• |
legal costs incurred in defending an action for a liability incurred as an officer or director of the company if the costs are incurred:
|
○ |
in defending or resisting proceedings in which the person is found to have a liability for which they cannot be indemnified as set out above;
|
○ |
in defending or resisting criminal proceedings in which the person is found guilty;
|
○ |
in defending or resisting proceedings brought by the Australian Securities & Investments Commission or a liquidator for a court order if the grounds for making the order are found by the court to have been
established (except costs incurred in responding to actions taken by the Australian Securities & Investments Commission or a liquidator as part of an investigation before commencing proceedings for the court order); or
|
○ |
in connection with proceedings for relief to the person under the Australian Corporations Act, in which the court denies the relief.
|
Item 7. |
Exemption from Registration Claimed.
|
Item 8. |
Exhibits.
|
Number
|
Description
|
|
Constitution of the Registrant (incorporated herein by reference to Exhibit 1.2 to the Registrant’s Registration Statement on Form 20-F, filed on October 30, 2024 (File No. 001-42128)).
|
||
Deposit Agreement among the Registrant, JPMorgan Chase Bank, N.A., as depositary, and all Holders and Beneficial Owners of American depositary receipts issued thereunder (incorporated herein by reference to Exhibit 2.1 to the Registrant’s
Registration Statement on Form 20-F, filed on October 30, 2024 (File No. 001-42128)).
|
||
Opinion of Herbert Smith Freehills.
|
||
Consent of PricewaterhouseCoopers.
|
||
Consent of Herbert Smith Freehills (included in Exhibit 5.1).
|
||
Power of Attorney (included on the signature pages of this registration statement).
|
||
Equity Incentive Plan Rules.
|
||
Telix Pharmaceuticals (US) Inc. Employee Stock Purchase Plan Rules.
|
||
Filing Fee Table.
|
Item 9. |
Undertakings.
|
Telix Pharmaceuticals Limited
|
||
By:
|
/s/ Dr. Christian Behrenbruch
|
|
Dr. Christian Behrenbruch
|
||
Group Chief Executive Officer and Managing Director
|
Signature
|
Title
|
|
/s/ Dr. Christian Behrenbruch
|
Group Chief Executive Officer and Managing Director
|
|
Dr. Christian Behrenbruch
|
(Principal Executive Officer)
|
/s/ Darren Smith
|
Group Chief Financial Officer
|
|
Darren Smith
|
(Principal Financial and Accounting Officer)
|
/s/ H Kevin McCann AO
|
Director and Chairman
|
|
H Kevin McCann AO
|
/s/ Mark Nelson
|
Director
|
|
Mark Nelson
|
/s/ Tiffany Olson
|
Director
|
|
Tiffany Olson
|
/s/ Jann Skinner
|
Director
|
|
Jann Skinner
|
Telix Pharmaceuticals (US) Inc.
|
||
Authorized Representative in the United States
|
||
By:
|
/s/ Christian Krautkramer
|
|
Name: Christian Krautkramer
|
||
Title: Group Deputy General Counsel
|
|
The Directors
Telix Pharmaceuticals Limited
55 Flemington Road
North Melbourne VIC 3051
Australia
|
19 December 2024
Matter 82783389
|
Dear Directors
|
Telix Pharmaceuticals Limited – Registration Statement on Form S-8
|
1 |
Documents examined and searches conducted and relied upon by us
|
(a) |
the Company’s EIP as most recently adopted by the Board on 13 November 2024 and the Company’s ESPP adopted by the Board on 12 December 2024;
|
(b) |
copies of notices of meeting for the annual general meetings of the Company for the years 2019 to 2024 (inclusive) (together, the Notices of Meetings) and resolutions passed at the meetings
convened by the Notices of Meetings;
|
(c) |
copies of the results of the annual general meetings of the Company for the years 2019 to 2024 (inclusive) as released to the Australian Securities Exchange;
|
(d) |
the prospectus issued by the Company dated 16 October 2017; and
|
(e) |
the constitution of the Company.
|
2 |
Assumptions in providing this letter
|
(a) |
that the shareholders’ meetings the subject of the Notices of Meetings were properly convened and that the resolutions passed at those shareholders’ meetings were properly passed;
|
(b) |
that the directors of the Company have acted in accordance with their duties in causing the Company to adopt the EIP and ESPP, and have acted, and will act, at all times in accordance with their duties in resolving to grant any
securities under such plans and to issue or allocate Shares pursuant to the vesting or exercise of securities issued under those plans;
|
Doc 2060552218
|
||
80 Collins Street Melbourne Vic 3000 Australia
GPO Box 128 Melbourne Vic 3001 Australia |
T +61 3 9288 1234 F +61 3 9288 1567
herbertsmithfreehills.com |
3 Opinion
|
(c) |
the genuineness of all signatures and the authenticity of all documents, instruments and certificates submitted to us as originals and the exact conformity with the authentic originals of all documents, instruments, and certificates
submitted to us as copies or forms or originals;
|
(d) |
all relevant documents continue in full force and effect and all signatures, seals, dates, duty stamps and markings appearing on all documents and copy documents submitted to us are genuine;
|
(e) |
any documents which purport to be governed by the law of any jurisdiction other than the laws of the Commonwealth of Australia are legal, valid and binding obligations of all parties to those documents and none of the execution,
delivery, or performance of any document by any party to the document violates or contravenes or is rendered invalid, not binding or unenforceable under any applicable law under any jurisdiction other than the law of the Commonwealth of
Australia;
|
(f) |
the filing of the Registration Statement or the consummation of the transactions contemplated therein does not violate or contravene the law of any jurisdiction or any applicable law under any jurisdiction (excluding the laws of the
Commonwealth of Australia);
|
(g) |
no person has or will engage in fraudulent or unconscionable conduct or conduct that is dishonest, misleading or deceptive or that is likely to mislead or deceive in relation to the EIP, ESPP or the Registration Statement;
|
(h) |
there is no bad faith, fraud, undue influence, coercion or duress or similar conduct on the part of the Company in relation to the EIP, ESPP or the Registration Statement;
|
(i) |
all information provided to us by or on behalf of officers of the Company was true, correct and complete when provided and remains so at the date of this letter, containing all information required, without us making any separate enquiry
or investigation;
|
(j) |
the Company is and will be able to pay its debts as and when they fall due and is otherwise solvent as at the time any Shares covered by the Registration Statement are allotted, issued and delivered; and
|
(k) |
all public records and searches that we have examined are accurate and the information disclosed by the searches conducted by us is true and complete and such information has not been altered and the searches did not fail to disclose any
information which had been delivered for registration, lodgement or filing against the Company’s records but which did not appear on the public records at the date of our search.
|
3 |
Opinion
|
4 Limitation
|
4 |
Limitations
|
5 |
Applicability
|
6 |
Consent
|
Tim McEwen
Partner
Herbert Smith Freehills
+61 3 9288 1549
+61 413 004 826
tim.mcewen@hsf.com
|
|
Herbert Smith Freehills LLP and its subsidiaries and Herbert Smith Freehills, an Australian Partnership ABN 98 773 882 646, are separate member firms of the international legal practice known as Herbert Smith Freehills.
|
Table of Contents
|
Introduction | 4 |
||
Part A: Making and accepting Offers
|
4 |
||
1
|
Offers of Incentive Securities
|
4
|
|
1.1
|
Board to make invitations
|
4 |
|
1.2
|
Information to be provided to Participants
|
4 |
|
1.3
|
Acceptance of Offer
|
5 |
|
1.4
|
Offer terms and conditions take precedence
|
5 |
|
1.5
|
No prohibited financial assistance
|
5 |
|
1.6
|
Quotation
|
5 |
|
Part B: Types of securities that may be offered
|
6 |
||
2
|
Rights
|
6 |
|
|
|||
2.1
|
Grant
|
6
|
|
2.2
|
Vesting and exercise
|
6
|
|
2.3
|
Allocation
|
7
|
|
2.4
|
Payment of cash equivalent
|
7
|
|
2.5
|
Share Appreciation Rights
|
7
|
|
2.6
|
Lapse of Rights
|
8
|
|
3
|
Options
|
8
|
|
3.1
|
Grant
|
8
|
|
3.2
|
Vesting and exercise
|
9
|
|
3.3
|
Allocation following exercise
|
9
|
|
3.4
|
Payment of cash equivalent
|
10
|
|
3.5
|
Lapse of Options
|
10
|
|
4 |
Restricted Shares
|
10 |
|
4.1 |
Allocation
|
10 |
|
4.2 |
Cessation of restrictions
|
11 |
|
4.3 |
Forfeiture of Restricted Shares
|
11 |
|
|
|||
Part C: General terms and conditions
|
12 |
||
5
|
Prohibited Dealings
|
12
|
|
6 |
Preventing inappropriate benefits
|
12
|
|
7 |
Forfeiture of Shares
|
13
|
|
8 |
Cessation of employment or engagement
|
13
|
|
9 |
Change of Control
|
14
|
|
9.1
|
Change of Control Events
|
14
|
|
9.2
|
Notification of Vesting
|
14
|
|
9.3
|
Treatment of Vested Incentive Securities
|
14
|
|
9.4
|
Acquisition of shares in Acquiring Company
|
15
|
|
10
|
Power to adjust Rights and/or Options and the Exercise Price
|
15
|
|
11
|
Dividends and other rights
|
16
|
|
11.1
|
Dividends and other rights associated with Shares
|
16
|
|
11.2
|
Dividend equivalent payments and other rights associated with Rights and Options 16
|
16 |
|
12
|
Withholding
|
17
|
13
|
Amendments
|
18
|
|
13.1
|
Power to make amendments
|
18
|
|
13.2
|
Restrictions on amendments
|
18
|
|
13.3
|
Notice of amendment
|
18
|
|
14
|
Participants based overseas
|
18
|
|
14.1
|
Overseas transfers
|
18
|
|
14.2
|
Non-Australian residents
|
19
|
|
15
|
Miscellaneous
|
19
|
|
15.1
|
Shares issued under the EIP
|
19
|
|
15.2
|
Rights and obligations of Participants
|
19
|
|
15.3
|
Power of the Board to administer the EIP
|
20
|
|
15.4
|
Waiver of terms and conditions
|
20
|
|
15.5
|
Application of constitution, Dodd-Frank Compensation Recovery Policy, Corporations Act and Listing Rules
|
20
|
|
15.6
|
Dispute or disagreement
|
21
|
|
15.7
|
Approved leave of absence
|
21
|
|
15.8
|
Communication
|
21
|
|
15.9
|
Data protection
|
22
|
|
15.10
|
Tax
|
22
|
|
15.11
|
Application of Act
|
22
|
|
15.12
|
Laws governing EIP
|
22
|
|
Part D: Definitions and interpretation
|
22
|
||
16
|
Definitions and interpretation
|
22
|
|
16.1
|
Definitions
|
22
|
|
16.2
|
Interpretation
|
26
|
Equity Incentive Plan Rules
|
• |
the process for making and accepting Offers under the EIP (Part A);
|
• |
the type of securities that may be offered (being Rights, Options and Restricted Shares) (Part B); and
|
• |
the general terms and conditions that apply to Shares and other securities under the EIP (Part C).
|
Part A: Making and accepting Offers
|
1.1 |
Board to make invitations
|
(a) |
The Board may, from time to time, in its absolute discretion invite Eligible Employees to participate in a grant of Incentive Securities, which may comprise any one or more of:
|
(i) |
Rights, including Share Appreciation Rights;
|
(ii) |
Options; and
|
(iii) |
Restricted Shares,
|
(Offer). |
(b) |
Offers will be made on the terms set out in the EIP and/or on any additional or alternative terms as the Board determines, as specified in the terms of an Offer.
|
1.2 |
Information to be provided to Participants
|
(a) |
the type and number of Incentive Securities being offered, or the method by which the number will be calculated;
|
(b) |
the amount (if any) that will be payable for the grant of Incentive Securities;
|
(c) |
any Vesting Conditions or other conditions that apply, including any Vesting Period;
|
(h) |
any restrictions (including the period of restriction) on Dealing in relation to a Restricted Share or Share allocated to the Eligible Employee under this EIP;
|
(i) |
any circumstances in which a Participant’s entitlement to Incentive Securities may be reduced or extinguished pursuant to rule 6(b); and
|
(j) |
any other information that is required by applicable law or applicable class order or instrument that is being relied on.
|
1.3 |
Acceptance of Offer
|
(a) |
Acceptance of an Offer must be made by the Eligible Employee in accordance with the instructions that accompany the Offer, or in any other way the Board determines.
|
1.4 |
Offer terms and conditions take precedence
|
1.5 |
No prohibited financial assistance
|
1.6 |
Quotation
|
Part B: Types of securities that may be offered
|
2.1 |
Grant
|
(a) |
Where an Eligible Employee has accepted an Offer to participate in a grant of Rights in accordance with rule 1.3(a), the Board will, subject to its discretion under rule 1.3(b), grant Rights to the Eligible Employee.
|
(b) |
For the purposes of these Rules, a Right includes a Share Appreciate Right granted under rule 2.5.
|
(c) |
Unless the Board determines otherwise:
|
(i) |
no payment is required for the grant of a Right;
|
(ii) |
Rights may not be registered in any name other than that of the Eligible Employee;
|
(iii) |
Rights may not be transferred, assigned, charged, mortgaged or otherwise dealt with by the Eligible Employee; and
|
(iv) |
the Board may determine that Rights will be deemed to be immediately and automatically exercised on Vesting, if specified in the terms of the Offer.
|
2.2 |
Vesting and exercise
|
(a) |
Subject to any express rule to the contrary, a Right will only Vest and become exercisable where each Vesting Condition, and all other relevant conditions advised to the Participant by the Board pursuant to rule 1.2, have been satisfied or
otherwise waived by the Board.
|
(c) |
The exercise of any Right granted under the EIP will be effected in the form and manner determined by the Board.
|
(d) |
Subject to rule 2.2(e), the Vesting and exercise of a Right will be satisfied by the Company allocating Shares to the Participant pursuant to rule 2.3.
|
(g) |
Vesting occurs upon notification from the Company (or its delegate) to the Participant that a Right has Vested pursuant to this rule 2.2. The Participant has no entitlement to receive a Share under rule 2.2(d) or a cash payment under rule
2.2(e) until the Rights have Vested, and if applicable, been exercised.
|
2.3 |
Allocation
|
(b) |
In the case of Rights that are Share Appreciation Rights, the number or fractional number of Shares allocated for each Right will be determined by the Board in accordance with rule 2.5(g).
|
(c) |
In the case of Rights held by or on behalf of a Participant who is a Director, Vested Rights must be satisfied by Shares that have been purchased on market, unless:
|
(i) |
no shareholder approval is required under the Listing Rules in respect of the Director’s participation in the EIP; or
|
(ii) |
shareholders have approved the Director’s participation in the EIP to the extent required under the Listing Rules.
|
2.4 |
Payment of cash equivalent
|
(b) |
The amount of the cash payment referred to in rule 2.4(a) will be:
|
(i) |
calculated by multiplying the number of Shares in respect of which Rights have Vested by the Current Market Price, in the case of Rights that are not Share Appreciation Rights;
|
(ii) |
the SARs Value of each Share Appreciation Right that is being settled in cash; and
|
(iii) |
in both cases, deemed to be inclusive of any mandatory superannuation contribution that applies to the cash payment.
|
(c) |
Where the Board determines that the payment under rule 2.4(a) is to be made in a currency other than Australian dollars, unless the Board determines otherwise, the foreign exchange rate applied will be the average closing exchange rate of
the relevant currency for the 5 days prior to the date of Vesting.
|
2.5 |
Share Appreciation Rights
|
(a) |
The Rights granted under this rule 2.5 are referred to as Share Appreciation Rights.
|
(d) |
The value realised for each Share Appreciation Right granted under rule 2.5(a) (SARs Value) is calculated at the time of exercise of the Share Appreciation Right as:
|
SARs Value for each Right exercised
|
=
|
Current Market Price at the time of exercise of the Share Appreciation Right
|
less
|
Notional Exercise Price
|
(i) |
first, calculating the SARs Value of each Share Appreciation Right;
|
(ii) |
second, multiplying the SARs Value for each relevant Share Appreciation Right by the total number of Share Appreciation Rights exercised (Total SARs Value); and
|
(iii) |
third, dividing the Total SARs Value by the Current Market Price (rounding up to the nearest whole number).
|
2.6 |
Lapse of Rights
|
(a) |
10 years after the date on which the Rights were allocated to the Participant, or any other date nominated as the expiry date in the Offer;
|
(b) |
the Right lapsing in accordance with a provision of these Rules (including in accordance with a term of an Offer);
|
(c) |
failure to meet a Vesting Condition or any other condition applicable to the Right within the Vesting Period; or
|
(d) |
the receipt by the Company of a notice in writing from a Participant to the effect that the Participant has elected to surrender the Right.
|
3.1 |
Grant
|
(b) |
Unless the Board determines otherwise:
|
(i) |
no payment is required for the grant of an Option;
|
(ii) |
Options may not be registered in any name other than that of the Eligible Employee; and
|
(iii) |
Options may not be transferred, assigned, charged, mortgaged or otherwise dealt with by the Eligible Employee.
|
3.2 |
Vesting and exercise
|
(a) |
Subject to any express rule to the contrary, an Option granted under the EIP will only Vest and become exercisable where each Vesting Condition, and all other relevant conditions advised to the Participant by the Board pursuant to rule 1.2,
have been satisfied or otherwise waived by the Board.
|
(d) |
Subject to rule 3.2(e), the exercise of an Option will be satisfied by the Company allocating Shares to the Participant pursuant to rule 3.3.
|
3.3 |
Allocation following exercise
|
(b) |
In the case of Options held by or on behalf of a Participant who is a Director, Vested Options must be satisfied by Shares that have been purchased on market, unless
|
(i) |
no shareholder approval is required under the Listing Rules in respect of the Director’s participation in the EIP; or
|
(ii) |
shareholders have approved the Director’s participation in the EIP to the extent required under the Listing Rules.
|
3.4 |
Payment of cash equivalent
|
(a) |
Where the Board exercises its discretion under rule 3.2(e) to make a cash payment to a Participant in lieu of an allocation of Shares, the Company must:
|
3.5 |
Lapse of Options
|
(a) |
10 years after the date on which the Options were allocated to the Participant, or any other date nominated as the expiry date in the Offer;
|
(b) |
the Option lapsing in accordance with a provision of these Rules (including in accordance with a term of an Offer);
|
(c) |
failure to meet a Vesting Condition or any other condition applicable to the Option within the Vesting Period; or
|
(d) |
the receipt by the Company of a notice in writing from a Participant to the effect that the Participant has elected to surrender the Option.
|
4.1 |
Allocation
|
(i) |
issuing Restricted Shares to;
|
(ii) |
procuring the transfer of Restricted Shares to; or
|
(iii) |
procuring the setting aside of Restricted Shares for, the Eligible Employee.
|
(c) |
Unless the Board determines otherwise:
|
(i) |
no payment is required for the grant of a Restricted Share; and
|
(ii) |
Restricted Shares may not be registered in any name other than that of the Eligible Employee or the Trustee.
|
4.2 |
Cessation of restrictions
|
(a) |
Subject to any express rule to the contrary, a Share only ceases to be a Restricted Share (i.e. Vests) where:
|
(ii) |
the Company notifies the Participant that the restrictions in respect of the Restricted Share have ceased or no longer apply.
|
(i) |
transfer the Share into the Participant’s name; or
|
(ii) |
sell the Share and pay the proceeds of sale (net of any applicable brokerage, commission, stamp duty or other transaction costs) to the Participant.
|
4.3 |
Forfeiture of Restricted Shares
|
(a) |
the Restricted Share being forfeited in accordance with a provision of these Rules (including in accordance a term of an Offer);
|
(b) |
the failure to meet a Vesting Condition or any other condition applicable to the Restricted Share within the Vesting Period; or
|
(c) |
the receipt by the Company of a notice in writing from a Participant to the effect that the Participant has elected to surrender the Restricted Share.
|
(a) |
Subject to the Securities Dealing Policy, any Dealing in respect of an Incentive Security is prohibited unless:
|
(i) |
the Board determines otherwise; or
|
(ii) |
the Dealing is required by law and the Participant has provided satisfactory evidence to the Company of that fact.
|
(b) |
Where, in the opinion of the Board, a Participant Deals with a Right or an Option in contravention of rule 5(a), the Right or Option will immediately lapse.
|
(a) |
Where, in the opinion of the Board:
|
(i) |
a Participant:
|
(A) |
has acted fraudulently or dishonestly;
|
(B) |
has engaged in gross misconduct;
|
(C) |
has engaged in an act which has brought the Company, the Group or any Group Company into disrepute;
|
(D) |
has breached his or her duties or obligations to the Group;
|
(E) |
is convicted of an offence or has a judgment entered against them in connection with the affairs of the Group; or
|
(ii) |
there is a Financial Misstatement Circumstance; or
|
(iv) |
the Company is required by or entitled under law or Company policy to reclaim remuneration from a Participant, the Board may determine that:
|
(v) |
any of the following held by or on behalf of the Participant:
|
(A) |
unvested Rights or Options;
|
(B) |
Vested but unexercised Rights or Options;
|
(C) |
Restricted Shares and/or Shares allocated under this EIP,
|
(vi) |
a Participant must pay or repay (as the case may be) to the Company as a debt:
|
(A) |
all or part of the net proceeds of sale where Shares allocated under the EIP have been sold;
|
(B) |
any cash payment received in lieu of an allocation of Shares pursuant to rules 2.4 or3.4; and/or
|
(C) |
any dividends received in respect of Shares allocated under the EIP.
|
(b) |
The Board may specify in an Offer additional circumstances in which a Participant’s entitlement to Incentive Securities may be reduced or extinguished.
|
(a) |
The Board, in its discretion, may determine that some or all of a Participant’s unvested Incentive Securities, as applicable:
|
(i) |
lapse;
|
(ii) |
are forfeited;
|
(iii) |
Vest (immediately or subject to conditions);
|
(iv) |
are only exercisable for a prescribed period and will otherwise lapse; and/or
|
(v) |
are no longer subject to some of the restrictions (including any Vesting Condition) that previously applied,
|
9.1 |
Change of Control Events
|
(a) |
Subject to rule 9.1(b), where there is:
|
(i) |
a Takeover Bid for Shares; or
|
(ii) |
another transaction, event or state of affairs,
|
(iii) |
a Change of Control Event does not include a listing of the Company or a Group Company or an internal reorganisation of the structure, business and/or assets of the Group; and
|
9.2 |
Notification of Vesting
|
9.3 |
Treatment of Vested Incentive Securities
|
(a) |
The Board has the discretion to determine the treatment of all Vested Incentive Securities (including those that Vest in accordance with rule 9.1) where a Change of Control Event occurs.
|
(b) |
Without limiting rule 9.3(a), where there is an actual change in the Control of the Company then, unless the Board determines otherwise:
|
(i) |
all Vested Options will be exercisable for a period specified by the Board from the actual change in the Control of the Company and will lapse if not exercised within the specified period; and
|
(ii) |
any restrictions on Dealing imposed by the Board on Vested Incentive Securities will cease to have effect.
|
9.4 |
Acquisition of shares in Acquiring Company
|
(a) |
a company (Acquiring Company) obtains Control of the Company as a result of a Change of Control Event; and
|
(b) |
the Company, the Acquiring Company and the Participant agree,
|
(c) |
Vesting of Rights; or
|
(d) |
exercise of Options,
|
(a) |
Rights and Options carry no entitlement to participate in new issues of Shares by the Company prior to the Vesting and exercise (if applicable) of the Right or Option.
|
(i) |
the number of Rights or Options to which the Participant is entitled;
|
(ii) |
the number of Shares to which the Participant is entitled upon Vesting and exercise of Rights or exercise of Options;
|
(iii) |
any amount payable on Vesting and exercise of Rights or exercise of Options (including the Exercise Price);
|
(iv) |
in the case of the Share Appreciation Rights, the Notional Exercise Price; or
|
(v) |
where appropriate, a combination of paragraphs (i), (ii), (iii) and/or (iv) above.
|
(c) |
Without limiting rule 10(a), if:
|
(e) |
The Board must, as soon as reasonably practicable after making any additional grants or adjustments under this rule 10 , give notice in writing to any affected Participant.
|
11.1 |
Dividends and other rights associated with Shares
|
(i) |
the Participant is entitled to receive all dividends and other distributions or benefits payable to the Participant or to the Trustee in respect of the Shares;
|
(ii) |
the Participant is entitled to exercise, or to direct the Trustee in writing how to exercise, the voting rights attaching to the Shares, either generally or in a particular case;
|
11.2 |
Dividend equivalent payments and other rights associated with Rights and Options
|
(c) |
Subject to the terms of any Offer, a dividend equivalent payment:
|
(i) |
will be approximately equal to the amount of dividends that would have been payable to the Participant had they been the owner of the Shares referred to in rule 11.2(b) during the Vesting Period;
|
(ii) |
will not be grossed up or otherwise adjusted to account for any tax consequences which would have applied if the Participant had actually been paid a dividend; and
|
(iii) |
may be satisfied through the allocation of Shares or payment of cash.
|
(i) |
income tax or employment taxes under any wage, withholding or other arrangements; or
|
(ii) |
any other tax, social security contributions or levy or charge of a similar nature,
|
(ii) |
the sale on behalf of the Participant of Shares allocated pursuant to these Rules for payment or reimbursement of these amounts, as well as the costs of any such sale;
|
(iii) |
a reduction in any amount payable to the Participant in lieu of an allocation of Shares under these Rules;
|
(iv) |
the Participant forgoing their entitlement to an equivalent number of Shares that would otherwise be allocated to the Participant; or
|
(c) |
Any amounts which are paid or payable for the purposes of these Rules are inclusive of the Group’s compulsory superannuation contribution (if applicable).
|
13.1 |
Power to make amendments
|
(a) |
Subject to rule 13.2, the Board may at any time by resolution:
|
(i) |
amend or add to (amend) all or any of the provisions of the EIP;
|
(ii) |
amend the terms or conditions of any Incentive Security granted under the EIP; or
|
(iii) |
suspend or terminate the operation of the EIP.
|
13.2 |
Restrictions on amendments
|
(b) |
to correct any manifest error or mistake; or
|
13.3 |
Notice of amendment
|
14.1 |
Overseas transfers
|
(a) |
the Participant or any Group Company would suffer a tax disadvantage in relation to their Incentive Securities (this being demonstrated to the satisfaction of the Board);
|
(b) |
the Company would be restricted in its ability to Vest Incentive Securities and/or allocate Shares to the Participant; or
|
(d) |
some or all of the Participant’s Restricted Shares or Rights will Vest;
|
(e) |
some or all of the Participant’s Options will Vest and become exercisable;
|
(f) |
some or all of the Participant’s Options or Rights will be settled in cash in lieu of Shares; or
|
(g) |
any other treatment that the Board determines will apply in relation to some or all of a Participant’s Incentive Securities,
|
14.2 |
Non-Australian residents
|
(c) |
To the extent of any inconsistency, any additional rules adopted by the Board under this rule will prevail over any other provision of these Rules.
|
15.1 |
Shares issued under the EIP
|
(b) |
If the Company is listed, the Company will apply for quotation of Shares issued under the EIP within the period required by the Listing Rules.
|
15.2 |
Rights and obligations of Participants
|
(c) |
These Rules will not form part of and are not incorporated into any contract of any Participant (whether or not they are an employee of the Group).
|
(d) |
The grant of Incentive Securities on a particular basis in any year does not create any right or expectation of the grant of Incentive Securities on the same basis, or at all, in any future year.
|
(e) |
No Participant has any right to compensation for any loss in relation to the EIP, including:
|
(i) |
any loss or reduction of any rights or expectations under the ElP in any circumstances or for any reason (including lawful or unlawful termination of employment or the employment relationship);
|
(ii) |
any exercise of a discretion or a decision taken in relation to a grant of Incentive Securities or in relation to the EIP, or any failure to exercise a discretion under these Rules;
|
(iii) |
the operation, suspension, termination or amendment of the EIP; or
|
(iv) |
lapse or forfeiture (as applicable) of any Incentive Securities.
|
(i) |
allocate Shares to the Participant in accordance with these Rules;
|
(ii) |
effect a forfeiture of Shares in accordance with these Rules (including rule 7 or the terms of an Offer); and
|
(iii) |
execute transfers of Shares in accordance with these Rules.
|
15.3 |
Power of the Board to administer the EIP
|
(a) |
The EIP is administered by the Board, which has power to:
|
(ii) |
delegate to any one or more persons for such period and on such conditions as it may determine the exercise of any of its powers or discretions arising under the EIP.
|
15.4 |
Waiver of terms and conditions
|
15.5 |
Application of constitution, Dodd-Frank Compensation Recovery Policy, Corporations Act and Listing Rules
|
15.6 |
Dispute or disagreement
|
15.7 |
Approved leave of absence
|
15.8 |
Communication
|
(a) |
Any notice or other communication provided under or in connection with the EIP may be given by personal delivery, by post or email or by posting or delivering it on the Company’s intranet to:
|
(i) |
in the case of a company, to its registered office;
|
(ii) |
in the case of an individual, to the individual’s last notified address; or
|
15.9 |
Data protection
|
(a) |
administering and maintaining Participant records;
|
(b) |
providing information to the Trustee, registrars, brokers, printers or third party administrators of the Plan;
|
(c) |
providing information to any regulatory authority (including the Australian Tax Office) where required under law; and
|
(d) |
providing information to future purchasers of a Group Company or the business in which the Participant works.
|
15.10 |
Tax
|
15.11 |
Application of Act
|
15.12 |
Laws governing EIP
|
16.1 |
Definitions
|
Defined term
|
Meaning
|
|||
ASX
|
ASX Limited ACN 008 624 691 or the Australian Securities Exchange, as the context requires.
|
|||
Board
|
the board of directors of the Company, any committee of the board or a duly authorised person or body to which the board has delegated its powers under this EIP.
|
|||
Casual Employee
|
an individual who is, or who might reasonably be expected to be, engaged to work the number of hours that are the pro rata equivalent of 40% or more of a comparable full-time position with a Group Company.
|
|||
Change of Control Event
|
has the meaning given in rule 9.1(a).
|
|||
Company
|
Telix Pharmaceuticals Limited ACN 616 620 369.
|
Defined term
|
Meaning
|
|||
Contractor
|
means:
(a) an individual with whom a Group Company has entered into a contract for the provision of services under which the individual performs work for a Group Company; or
(b) a company with whom a Group Company has entered into a contract for the provision of services under which an individual who is a director of the company or their
spouse, performs work for a Group Company, where the individual who performs the work under the contract is, or might reasonably be expected to be, engaged to work the number of hours that are the pro rata equivalent of 40% or more of a
comparable full-time position with a Group Company.
|
|||
Control
|
has the meaning given in section 50AA of the Corporations Act.
|
|||
Corporations Act
|
the Corporations Act 2001 (Cth).
|
|||
Current Market Price
|
in relation to a Share:
(a) where the Company is listed, the arithmetic average of the volume weighted average market price (rounded to the nearest cent), as that term is defined in the Listing Rules, during
the previous twenty trading days (or such other period as determined by the Board and specified in the Offer); or
(b) any other calculation as determined by the Board (whether or not the Company is listed).
|
|||
Deal or Dealing
|
in relation to an Incentive Security or Share (as the case may be), any dealing, including but not limited to:
(a) a sale, transfer, assignment, encumbrance, option, swap, or any other alienation of all or any part of the rights attaching to the Incentive Security or Share;
(b) any attempt to do any of the actions set out in paragraph (a) above; and
(c) any hedging (including any dealing with a derivative instrument intended to “lock in” a profit relating to an Incentive Security), and any other transactions in financial products
that operate to limit the economic risk associated with holding an Incentive Security.
|
|||
Director
|
a director of the Company.
|
|||
EIP or Plan
|
the Telix Pharmaceuticals Limited Equity Incentive Plan as set out in these Rules.
|
Defined term
|
Meaning
|
|||
Eligible Employee
|
means:
(a) a full time or part time employee of a Group Company (including a Director employed in an executive capacity);
(b) a non-executive Director of a Group Company;
(c) a Casual Employee; or
(d) a Contractor.
|
|||
Exercise Price
|
the amount payable to exercise an Option following Vesting as set out in an Offer (as adjusted or amended in accordance with these Rules).
|
|||
Financial Misstatement Circumstance
|
a material misstatement or omission in the financial statements of a Group Company or any other circumstances or events which, in the opinion of the Board, may, or are likely to, affect the Group’s financial soundness or require re-statement
of the Group’s financial accounts, including, without limitation, as a result of misrepresentations, errors, omissions or negligence.
|
|||
Group
|
the Company and each Related Body Corporate of the Company.
|
|||
Group Company
|
a member of the Group.
|
|||
Incentive Security
|
a Restricted Share, Right or Option (as the case may be).
|
|||
Listing Rules
|
the official Listing Rules of the ASX and any other exchange on which the Company is listed as they apply to the Company from time to time.
|
|||
Notional Exercise Price
|
has the meaning given in rule 2.5(b).
|
|||
Offer
|
an invitation to an Eligible Employee made by the Board under rule 1.1 to apply for, participate in, or receive (as applicable), a grant of, Incentive Securities.
|
|||
Option
|
an entitlement to receive a Share (or, in certain circumstances, to a cash payment in lieu of a Share) subject to satisfaction of applicable conditions (including any Vesting Condition) and compliance with the applicable exercise procedure
(including payment of any applicable Exercise Price).
|
|||
Participant
|
an Eligible Employee who has been allocated an Incentive Security or Share under the terms of this EIP from time to time.
|
|||
Related Body Corporate
|
has the meaning given in section 50 of the Corporations Act.
|
|||
Restricted Share
|
a Share allocated in accordance with rule 4.1 that is subject to restrictions on Dealing, Vesting Conditions and/or other restrictions or conditions.
|
Defined term
|
Meaning
|
|||
Right
|
an entitlement to a Share (or, in certain circumstances, to a cash payment in lieu of a Share) subject to satisfaction of applicable conditions (including any Vesting Condition), including a Share Appreciation Right (in which case the
entitlement may be to a part of a Share).
|
|||
Rules
|
the terms and conditions of the EIP as set out in this document as amended from time to time.
|
|||
SARs Value
|
has the meaning given in rule 2.5(d).
|
|||
Securities Dealing Policy
|
the Company’s Policy for Dealing in Securities (as amended or replaced from time to time) or such other Group policy in relation to trading or Dealing in Shares as applicable from time to time.
|
|||
Share
|
a fully paid ordinary share in the capital of the Company (where a reference to a Share includes a reference to a Restricted Share).
|
|||
Share Appreciation Right
|
a Right granted under rule 2.5.
|
|||
Takeover Bid
|
has the meaning given in section 9 of the Corporations Act.
|
|||
Tax
|
Includes any tax, levy, impost, GST, deduction, charge, rate, contribution, duty or withholding which is assessed (or deemed to be assessed), levied, imposed or made by any government or any governmental, semi-governmental or judicial entity
or authority together with any interest, penalty, fine, charge, fee or other amount assessed (or deemed to be assessed) levied, imposed or made on or in respect of any or all of the foregoing.
|
|||
Total SARs Value
|
Has the meaning given in rule 2.5(g)(ii)
|
|||
Trust Deed
|
in relation to an Offer, any trust deed nominated by the Company as the Trust Deed for the purposes of the Offer, as amended from time to time.
|
|||
Trustee
|
the trustee under the Trust Deed.
|
|||
Vest or Vesting
|
the process by which the holder of an Incentive Security becomes entitled to:
(a) in the case of a Right, exercise the Right and be allocated a Share in accordance with rules 2.2 and 2.3;
(b) in the case of an Option, exercise the Option and be allocated a Share in accordance with rule 3.2 and 3.3;
(c) in the case of a Restricted Share, have all restrictions on disposing of or otherwise Dealing with the Restricted Share cease in accordance with rule 4.2 (other than any additional restrictions imposed by the Board under rule
5(d)),
following the satisfaction of all Vesting Conditions that apply to that Incentive Security.
|
Defined term
|
Meaning
|
|||
Vesting Condition
|
performance, service or other conditions that must be satisfied or circumstances which must exist before an Incentive Security Vests under these Rules.
|
|||
Vesting Period
|
the prescribed period for satisfaction of a Vesting Condition, advised to a participant by the Board under rule 1.2.
|
16.2 |
Interpretation
|
(a) |
headings are for convenience only and do not affect the interpretation of the EIP unless the context requires otherwise;
|
(b) |
any reference in the EIP to any statute or statutory instrument includes a reference to that statute or statutory instrument as amended, consolidated, re- enacted or replaced from time to time;
|
(c) |
a reference to any agreement or document includes a reference to that agreement or document as amended, novated, supplemented or amended from time to time;
|
(d) |
any words denoting the singular include the plural and words denoting the plural include the singular;
|
(e) |
where any word or phrase is given a definite meaning in this EIP, any part of speech or other grammatical form of that word or phrase has a corresponding meaning;
|
(f) |
the word “includes” in any form is not a word of limitation; and
|
(g) |
any determination, decision or exercise of power, by the Board will be at its absolute discretion
|
1. |
Definitions
|
b) |
“Committee” means the People, Culture, Nomination and Remuneration Committee of Telix’s Board of Directors (the “Board”).
|
c) |
“Covered Person” means a person who served as an Executive Officer at any time during the performance period for the applicable Incentive-Based Compensation.
|
g) |
“Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.
|
2. |
Recovery of Erroneously Awarded Compensation
|
3. |
Interpretation and Administration
|
1. Introduction
|
3
|
||
(a)
|
Purpose
|
3
|
|
(b)
|
Components
|
3
|
|
2. Definitions
|
3
|
||
3. Eligibility
|
6
|
||
(a)
|
Broad-Based Stock Plan
|
6
|
|
(b)
|
Limitations
|
6
|
|
4. Participation
|
6
|
||
(a)
|
Enrollment Agreement
|
6
|
|
(b)
|
After-Tax Contributions
|
6
|
|
(c)
|
Whole Shares
|
6
|
|
(d)
|
No Mandatory Participation
|
6
|
|
5. Contributions
|
6
|
||
(a)
|
Elections
|
7
|
|
(b)
|
Other Benefits
|
7
|
|
(c)
|
Notional Account
|
7
|
|
(d)
|
Contribution Changes
|
7
|
|
(e)
|
Termination of Employee Status
|
7
|
|
(f)
|
Leave of Absence
|
7
|
|
6. Offering Periods and Contribution Periods
|
8
|
||
(a)
|
Timing
|
8
|
|
(b)
|
Option to Purchase Shares
|
8
|
|
(c)
|
Exercise of Options
|
8
|
|
(d)
|
Delivery of Shares
|
8
|
|
(e)
|
Mandatory Holding Periods
|
8
|
|
(f)
|
Currency Exchange Rate
|
9
|
|
(g)
|
Shareholder Rights
|
9
|
|
7. Shares
|
9
|
||
(a)
|
Share Reserve
|
9
|
|
(b)
|
Dividends
|
9
|
|
(c)
|
Registration of Shares
|
9
|
|
(d)
|
Conditions Upon Issuance of Shares
|
10
|
|
8. Administration
|
10
|
||
(a)
|
Plan Administrator
|
10
|
|
(b)
|
Authority
|
10
|
|
(c)
|
Binding Decisions
|
11
|
|
(d)
|
Delegation
|
11
|
|
9. General Provisions
|
11
|
||
(a)
|
Nontransferability
|
11
|
|
(b)
|
Accounts
|
11
|
|
(c)
|
Adjustments Upon Changes in Capitalization
|
12
|
|
(d)
|
Amendment or Termination
|
12
|
|
(e)
|
Notices
|
12
|
|
(f)
|
Term of Plan
|
12
|
|
(g)
|
Treatment of Plan Expenses
|
12
|
|
(h)
|
No Guarantee of Employment or Benefits
|
12
|
|
(i)
|
Indemnification
|
12
|
|
(j)
|
Withholding
|
13
|
(k)
|
Section 409A
|
13
|
|
(l)
|
Applicable Law
|
13
|
|
(m)
|
Severability
|
13
|
|
(n)
|
Headings
|
13
|
1.
|
Introduction
|
2.
|
Definitions
|
3.
|
Eligibility
|
4.
|
Participation
|
5.
|
Contributions
|
6.
|
Offering Periods and Contribution Periods
|
7.
|
Shares
|
8.
|
Administration
|
9.
|
General Provisions
|
Security
Type
|
Security Class
Title
|
Fee
Calculation
Rule
|
Amount
Registered(1)
|
Proposed
Maximum
Offering Price
Per Unit
|
Maximum
Aggregate
Offering Price
|
Fee Rate
|
Amount of
Registration Fee
|
||||||||||||||||
Newly Registered Securities
|
|||||||||||||||||||||||
Fees to be Paid
|
Equity
|
Equity Incentive Plan Rules, Ordinary Shares, no par value(2)
|
Rules 457(c) and 457(h)
|
41,917,933
|
(3)
|
$
|
12.17
|
(4)
|
$
|
510,065,293.25
|
(4)
|
0.00015310
|
$
|
78,091.00
|
|||||||||
Fees to be Paid
|
Equity
|
Telix Pharmaceuticals (US) Inc. Employee Stock Plan Purchase Rules, Ordinary Shares, no par value(2)
|
Rules 457(c) and 457(h)
|
1,351,000(5)
|
$
|
13.68
|
(6)
|
$
|
18,476,951.50
|
(6)
|
0.00015310
|
$
|
2,828.82
|
||||||||||
Total Offering Amounts
|
$
|
528,542,244.75
|
$
|
80,919.82
|
|||||||||||||||||||
Total Fees Previously Paid
|
—
|
||||||||||||||||||||||
Total Fee Offsets
|
$
|
34,251.83
|
|||||||||||||||||||||
Net Fee Due
|
$
|
46,667.99
|
(1) |
In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall be deemed to cover any additional securities that may from time to time be
offered or issued to prevent dilution resulting from share splits, share dividends or similar transactions.
|
(2) |
These shares may be represented by the Registrant’s American Depositary Shares (the “ADSs”). Each ADS represents one ordinary share. ADSs issuable upon deposit of the ordinary shares registered hereby have
been registered under a separate registration statement on Form F-6 (File No. 333-282705), as amended, by Telix Pharmaceuticals Limited (the “Registrant”).
|
(3) |
Consists of 41,917,933 ADSs, representing 41,917,933 ordinary shares issuable under the Registrant’s Equity Incentive Plan Rules (the “EIP”).
|
(4) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, and based on (a) $6.21, the weighted average exercise price per share of the
16,639,094 shares subject to outstanding share options under the EIP, at exercise prices ranging from $2.79 to $11.75 per share, and (b) $16.09, the average of the high and low sales prices of the Registrant’s ADSs as quoted on the Nasdaq
Global Select Market on December 13, 2024, divided by 1, the ordinary share-to-ADS-ratio, for the (x) 22,982,839 shares that remain issuable under the EIP for the three year period following shareholder approval at the Registrant's 2024
Annual General Meeting pursuant to Exception 13(b) to Listing Rule 7.1 of the Australian Securities Exchange, plus (y) 2,296,000 shares issuable upon exercise of outstanding share rights, rounded to the nearest cent. The weighted average
exercise price of the outstanding share options and exercise price range are expressed in U.S. dollars based on an assumed exchange rate of A$1.00 to US$0.6367, which was the official exchange rate published by the Reserve Bank of
Australia on December 13, 2024.
|
(5) |
Consists of 1,351,000 ADSs, representing 1,351,000 ordinary shares issuable under the Telix Pharmaceuticals (US) Inc. Employee Stock Plan Purchase Rules.
|
(6) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h) of the Securities Act, and based on 85% of $16.09, the average of the high and low sale prices of the Registrant’s ADSs as quoted on
the Nasdaq Global Select Market on December 13, 2024, divided by 1, the then ordinary share-to-ADS ratio. Pursuant to the Telix Pharmaceuticals (US) Inc. Employee Stock Purchase Plan Rules, the purchase price of the shares of ordinary
shares reserved for issuance thereunder will be 85% of the fair market value of one ordinary share on the offering date or on the purchase date, whichever is lower.
|
Registrant or
Filer Name
|
Form or
FilingType
|
File
Number
|
Initial
Filing
Date
|
Filing
Date
|
Fee Offset
Claimed
|
Security
Type
Associated with Fee Offset Claimed
|
Security Title Associated
with Fee
Offset
Claimed
|
Unsold
Securities
Associated
with
Fee Offset
Claimed
|
Unsold
Aggregate
Offering
Amount
Associated
with Fee
Offset
Claimed
|
Fee
Paid
with
Fee
Offset
Source
|
||||||||||||||||||||||||||||
Rule 457(p)
|
||||||||||||||||||||||||||||||||||||||
Fee Offset Claims
|
Telix Pharmaceuticals Limited
|
Form F-1
|
333-279471
|
5/17/2024
|
—
|
$
|
34,251.83
|
(7)
|
Equity
|
Ordinary Shares, no par value
|
—
|
$
|
232,058,500.00
|
|||||||||||||||||||||||||
Fee Offset Sources
|
Telix Pharmaceuticals Limited
|
Form F-1
|
333-279471
|
—
|
5/17/2024
|
—
|
—
|
—
|
—
|
—
|
$
|
34,251.83
|
(7)
|
(7) |
The Registrant previously paid a registration fee of $34,251.83 in connection with its Registration Statement on Form F-1, initially filed on May 17, 2024 and amended on June 5, 2024 (File No. 333-279471)
(the “Form F-1”). The Form F-1 was not declared effective by the Securities and Exchange Commission, and no securities were issued or sold thereunder. The Form F-1 was withdrawn by the Registrant by filing a Form RW on June 14, 2024. In
accordance with Rule 457(p) under the Securities Act, the total amount of the registration fee due in connection with this Registration Statement is offset by $34,251.83, representing the fee paid in connection with the Form F-1.
|